PEPTIDE DEFORMYLASE AS A NOVEL TARGET OF ANTIMICROBIALS

During the preceding decades various pathogenic microorganism have developed multidrug resistance. Discovery and development of new antimicrobial with novel targets in microbes are in great demand in order to reduce multiresistance infection and duration of chemotherapy. Peptide deformylase is an essential enzyme involved in bacterial protein biosynthesis and maturation. Its absence in eukaryotic organisms makes it an attractive target for antimicrobial chemotherapy. A number of peptide deformylase inhibitors have been discovered. Peptide deformylase inhibitors such as BB-81384, BB83698 and VIC-104959 (LBM-415; NVP-peptide deformylase-713) have entered into clinical trials in humans as oral and parenteral agents for treatment of infections caused by Gram-positive and Gram-negative bacteria.